US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Crinetics Pharmaceuticals Inc.

47.69

-0.9200-1.89%

Pre-market: 48.300.6100+1.28%05:03 EST

Volume:957.80K

Turnover:45.89M

Market Cap:4.53B

PE:-10.50

High:49.14

Open:48.97

Low:47.40

Close:48.61

52wk High:55.47

52wk Low:24.10

Shares:94.89M

Float Shares:92.77M

Volume Ratio:1.01

T/O Rate:1.03%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-4.5405

EPS(LYR):-3.6939

ROE:-44.42%

ROA:-28.00%

PB:4.22

PE(LYR):-12.91

Loading ...

Overview Company News Filings

Crinetics Pharmaceuticals Grants $577,000 Severance and Bonus Eligibility to Departing Chief Medical Officer

Crinetics Pharmaceuticals Doses First Patient in Phase 3 Atumelnant Trial for Congenital Adrenal Hyperplasia

Crinetics Announces First Patient Dosed in Pivotal Adult Trial of Atumelnant in Congenital Adrenal Hyperplasia (Cah)

THOMSON REUTERS

Crinetics Pharmaceuticals Grants Stock Options and RSUs to New Employees Under 2021 Inducement Plan

Crinetics Pharmaceuticals Announces December 2025 Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS

Did First-in-Human BRAVESST2 Trial of CRN09682 Just Shift Crinetics Pharmaceuticals' (CRNX) Investment Narrative?

Simply Wall St.

Crinetics Pharmaceuticals Chief Medical and Development Officer Dana Pizzuti Reports Disposal of Common Shares

BRIEF-Crinetics Announces First Patient Dosed In Phase 1/2 Trial Evaluating Crn09682

Crinetics Announces First Patient Dosed in Phase 1/2 Trial Evaluating Crn09682 for the Treatment of Neuroendocrine Tumors and Other Somatostatin Receptor 2-Expressing Tumors

THOMSON REUTERS

Crinetics Pharmaceuticals Doses First Patient in Phase 1/2 Trial of CRN09682 for Neuroendocrine Tumors

Why Crinetics Pharmaceuticals (CRNX) Is Up 6.3% After Pivotal Phase 3 Paltusotine Trial Launch

Simply Wall St.

Crinetics randomizes first patient in CAREFNDR trial

Crinetics Launches Phase 3 Trial of Paltusotine for Carcinoid Syndrome

Crinetics Announces First Patient Randomized in Pivotal Phase 3 Carefndr Trial Evaluating Paltusotine in Carcinoid Syndrome

THOMSON REUTERS

Crinetics Pharmaceuticals Announces November 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Crinetics Pharmaceuticals Q3 Net Income USD -130.091 Million

BRIEF-Crinetics Pharmaceuticals Announces November 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Crinetics Pharmaceuticals Grants Stock Options and RSUs to New Employees Under 2021 Inducement Plan

Cantor Fitzgerald Sticks to Its Buy Rating for Crinetics Pharmaceuticals (CRNX)

Crinetics price target raised to $45 from $40 at Goldman Sachs

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/CRNX/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CRNX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CRNX\",,,,,undefined,":{"symbol":"CRNX","market":"US","secType":"STK","nameCN":"Crinetics Pharmaceuticals Inc.","latestPrice":47.69,"timestamp":1766005200000,"preClose":48.61,"halted":0,"volume":957804,"hourTrading":{"tag":"盘前","latestPrice":48.3,"preClose":47.69,"latestTime":"05:03 EST","volume":1,"amount":48.3,"timestamp":1766052205730},"delay":0,"floatShares":92774391,"shares":94891840,"eps":-4.540471,"marketStatus":"Pre-Mkt","change":-0.92,"latestTime":"12-18 08:41:23 EST","open":48.965,"high":49.14,"low":47.4,"amount":45893566.57062,"amplitude":0.035795,"askPrice":55.68,"askSize":100,"bidPrice":42.07,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-4.540471,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1766068200000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1531886400000,"exchange":"NASDAQ","adjPreClose":47.69,"preHourTrading":{"tag":"盘前","latestPrice":48.3,"preClose":47.69,"latestTime":"05:03 EST","volume":1,"amount":48.3,"timestamp":1766052205730},"postHourTrading":{"tag":"盘后","latestPrice":47.69,"preClose":47.69,"latestTime":"19:27 EST","volume":158328,"amount":7550662.72,"timestamp":1766017664060},"volumeRatio":1.0052966253433873,"impliedVol":0.8432,"impliedVolPercentile":0.992},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CRNX\",,,,,undefined,":{"symbol":"CRNX","floatShares":92774391,"roa":"-28.00%","roe":"-44.42%","lyrEps":-3.693945,"volumeRatio":1.0052966253433873,"shares":94891840,"dividePrice":0,"high":49.14,"amplitude":0.035795,"preClose":48.61,"low":47.4,"week52Low":24.1,"pbRate":"4.22","psRate":"2948.14","week52High":55.465,"institutionHeld":0,"latestPrice":47.69,"eps":-4.540471,"divideRate":0,"volume":957804,"delay":0,"ttmEps":-4.540471,"open":48.965,"prevYearClose":51.13,"prevWeekClose":50.49,"prevMonthClose":45.56,"prevQuarterClose":41.65,"fiveDayClose":48.06,"twentyDayClose":43.01,"sixtyDayClose":35.86},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CRNX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-06","symbol":"CRNX","fiscalQuarterEnding":"2025/09","expectedEps":-1.27,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1762405200000,"reportTimeType":"post","actualEps":-1.38},{"market":"US","date":"2025-08-07","symbol":"CRNX","fiscalQuarterEnding":"2025/06","expectedEps":-1.13,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1754539200000,"reportTimeType":"post","actualEps":-1.23},{"market":"US","date":"2025-05-08","symbol":"CRNX","fiscalQuarterEnding":"2025/03","expectedEps":-0.99,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1746676800000,"reportTimeType":"post","actualEps":-1.04},{"market":"US","date":"2025-02-27","symbol":"CRNX","fiscalQuarterEnding":"2024/12","expectedEps":-0.92,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1740632400000,"reportTimeType":"post","actualEps":-0.88},{"market":"US","date":"2024-11-12","symbol":"CRNX","fiscalQuarterEnding":"2024/09","expectedEps":-0.91,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"post","actualEps":-0.96}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CRNX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CRNX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3125,"buy":0.5625,"hold":0.125,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5625,"analysts":16,"updateTime":1752123600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/CRNX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"CRNX","date":"2025-12-17","current":-10.503316,"percent":0.317854,"low":-21.135071,"twenty":-13.010724,"median":-9.228039,"eighty":-7.268484,"high":-4.749275,"avg":-10.297831,"sd":3.670835,"marketCap":4612692342},"quantilePoints":[{"date":"2020-12-18","current":-6.483804,"twenty":-29.356932,"median":-12.252824,"eighty":-8.417946,"marketCap":432599389},{"date":"2020-12-24","current":-6.779868,"twenty":-29.356932,"median":-12.231801,"eighty":-8.400588,"marketCap":452352786},{"date":"2020-12-31","current":-6.962441,"twenty":-29.220494,"median":-12.204504,"eighty":-8.371889,"marketCap":464534048},{"date":"2021-01-08","current":-7.485487,"twenty":-29.168193,"median":-12.152639,"eighty":-8.30352,"marketCap":499431715},{"date":"2021-01-15","current":-7.011785,"twenty":-28.763427,"median":-12.118146,"eighty":-8.241806,"marketCap":467826280},{"date":"2021-01-22","current":-7.510159,"twenty":-28.649728,"median":-12.082916,"eighty":-8.207549,"marketCap":501077832},{"date":"2021-01-29","current":-7.080866,"twenty":-28.565591,"median":-12.052909,"eighty":-8.173666,"marketCap":472435406},{"date":"2021-02-05","current":-7.821027,"twenty":-28.474633,"median":-12.006229,"eighty":-8.094973,"marketCap":521818898},{"date":"2021-02-12","current":-7.998665,"twenty":-28.39277,"median":-11.934263,"eighty":-8.094973,"marketCap":533670936},{"date":"2021-02-19","current":-8.146697,"twenty":-28.342742,"median":-11.917885,"eighty":-8.049585,"marketCap":543547635},{"date":"2021-02-26","current":-7.5447,"twenty":-28.299536,"median":-11.901507,"eighty":-8.013901,"marketCap":503382395},{"date":"2021-03-05","current":-7.455881,"twenty":-28.210852,"median":-11.819616,"eighty":-7.994013,"marketCap":497456376},{"date":"2021-03-12","current":-8.353942,"twenty":-28.110797,"median":-11.770481,"eighty":-7.967844,"marketCap":557375013},{"date":"2021-03-19","current":-8.136828,"twenty":-28.028935,"median":-11.704968,"eighty":-7.967844,"marketCap":542889188},{"date":"2021-03-26","current":-7.811158,"twenty":-27.933428,"median":-11.63051,"eighty":-7.964775,"marketCap":521160452},{"date":"2021-04-01","current":-7.159568,"twenty":-27.897044,"median":-11.588591,"eighty":-7.902113,"marketCap":528462016},{"date":"2021-04-09","current":-8.693397,"twenty":-27.831099,"median":-11.529808,"eighty":-7.891629,"marketCap":641677004},{"date":"2021-04-16","current":-8.520242,"twenty":-27.812907,"median":-11.442768,"eighty":-7.902113,"marketCap":628896091},{"date":"2021-04-23","current":-8.749418,"twenty":-27.771976,"median":-11.356433,"eighty":-7.924226,"marketCap":645812005},{"date":"2021-04-30","current":-8.816199,"twenty":-27.746962,"median":-11.254127,"eighty":-7.946642,"marketCap":650741252},{"date":"2021-05-07","current":-8.034776,"twenty":-27.710579,"median":-11.235459,"eighty":-7.946642,"marketCap":637583572},{"date":"2021-05-14","current":-7.684202,"twenty":-27.660551,"median":-11.195212,"eighty":-7.888353,"marketCap":609764477},{"date":"2021-05-21","current":-7.968451,"twenty":-27.59688,"median":-11.161659,"eighty":-7.887379,"marketCap":632320500},{"date":"2021-05-28","current":-8.314288,"twenty":-27.519566,"median":-11.118972,"eighty":-7.887914,"marketCap":659763661},{"date":"2021-06-04","current":-8.025301,"twenty":-27.35584,"median":-11.088558,"eighty":-7.887914,"marketCap":636831704},{"date":"2021-06-11","current":-8.044251,"twenty":-27.3331,"median":-11.053337,"eighty":-7.887914,"marketCap":638335439},{"date":"2021-06-18","current":-10.019782,"twenty":-27.32173,"median":-11.012698,"eighty":-7.890108,"marketCap":795099796},{"date":"2021-06-25","current":-9.294947,"twenty":-27.242141,"median":-10.995297,"eighty":-7.897712,"marketCap":737581939},{"date":"2021-07-02","current":-9.474972,"twenty":-27.173922,"median":-10.932506,"eighty":-7.919715,"marketCap":751867420},{"date":"2021-07-09","current":-9.943983,"twenty":-27.137539,"median":-10.908238,"eighty":-7.937761,"marketCap":789084857},{"date":"2021-07-16","current":-9.342322,"twenty":-27.101155,"median":-10.846994,"eighty":-7.959754,"marketCap":741341276},{"date":"2021-07-23","current":-9.465497,"twenty":-26.966991,"median":-10.80828,"eighty":-7.965426,"marketCap":751115552},{"date":"2021-07-30","current":-8.517999,"twenty":-26.807814,"median":-10.776036,"eighty":-7.967911,"marketCap":675928810},{"date":"2021-08-06","current":-8.337975,"twenty":-26.739595,"median":-10.735036,"eighty":-7.968451,"marketCap":661643329},{"date":"2021-08-13","current":-9.407112,"twenty":-26.603157,"median":-10.717996,"eighty":-7.968451,"marketCap":836828438},{"date":"2021-08-20","current":-8.819695,"twenty":-26.553129,"median":-10.689519,"eighty":-7.970477,"marketCap":784573652},{"date":"2021-08-27","current":-9.89733,"twenty":-26.503102,"median":-10.6786,"eighty":-7.987732,"marketCap":880436748},{"date":"2021-09-03","current":-10.425582,"twenty":-26.446253,"median":-10.645321,"eighty":-7.995885,"marketCap":927428462},{"date":"2021-09-10","current":-9.800131,"twenty":-26.264335,"median":-10.629198,"eighty":-7.997042,"marketCap":871790273},{"date":"2021-09-17","current":-9.635317,"twenty":-26.123349,"median":-10.607627,"eighty":-7.99806,"marketCap":857128858},{"date":"2021-09-24","current":-8.874634,"twenty":-26.023294,"median":-10.576486,"eighty":-8.000898,"marketCap":789460791},{"date":"2021-10-01","current":-8.959154,"twenty":-24.761242,"median":-10.553033,"eighty":-8.005527,"marketCap":796979465},{"date":"2021-10-08","current":-8.240731,"twenty":-23.773189,"median":-10.492287,"eighty":-8.011129,"marketCap":733070734},{"date":"2021-10-15","current":-8.236505,"twenty":-23.618977,"median":-10.471142,"eighty":-8.01938,"marketCap":732694800},{"date":"2021-10-22","current":-11.634891,"twenty":-23.506395,"median":-10.46987,"eighty":-8.024509,"marketCap":1035005025},{"date":"2021-10-29","current":-13.215665,"twenty":-23.418832,"median":-10.492287,"eighty":-8.027254,"marketCap":1175625929},{"date":"2021-11-05","current":-13.35881,"twenty":-23.379517,"median":-10.552734,"eighty":-8.031346,"marketCap":1315682448},{"date":"2021-11-12","current":-12.870423,"twenty":-23.279444,"median":-10.563952,"eighty":-8.033556,"marketCap":1267582229},{"date":"2021-11-19","current":-13.052371,"twenty":-23.221008,"median":-10.599438,"eighty":-8.034381,"marketCap":1285501919},{"date":"2021-11-26","current":-11.682973,"twenty":-23.206712,"median":-10.620299,"eighty":-8.038017,"marketCap":1150632678},{"date":"2021-12-03","current":-11.807464,"twenty":-23.15078,"median":-10.659957,"eighty":-8.043427,"marketCap":1162893518},{"date":"2021-12-10","current":-12.587925,"twenty":-23.050707,"median":-10.672503,"eighty":-8.050409,"marketCap":1239759554},{"date":"2021-12-17","current":-11.730854,"twenty":-22.824303,"median":-10.684059,"eighty":-8.067845,"marketCap":1155348386},{"date":"2021-12-23","current":-12.693263,"twenty":-22.587462,"median":-10.69865,"eighty":-8.080293,"marketCap":1250134111},{"date":"2021-12-31","current":-13.603003,"twenty":-22.557248,"median":-10.726653,"eighty":-8.085586,"marketCap":1339732557},{"date":"2022-01-07","current":-12.128267,"twenty":-22.43404,"median":-10.764825,"eighty":-8.109087,"marketCap":1194488760},{"date":"2022-01-14","current":-11.496237,"twenty":-22.309681,"median":-10.795382,"eighty":-8.129763,"marketCap":1132241418},{"date":"2022-01-21","current":-9.083033,"twenty":-22.304875,"median":-10.77043,"eighty":-8.136828,"marketCap":894569750},{"date":"2022-01-28","current":-8.551553,"twenty":-22.278215,"median":-10.733194,"eighty":-8.141763,"marketCap":842225395},{"date":"2022-02-04","current":-8.379182,"twenty":-22.216011,"median":-10.708323,"eighty":-8.141763,"marketCap":825248847},{"date":"2022-02-11","current":-8.872356,"twenty":-22.038282,"median":-10.684059,"eighty":-8.146697,"marketCap":873820636},{"date":"2022-02-18","current":-9.351167,"twenty":-21.949418,"median":-10.672503,"eighty":-8.154662,"marketCap":920977713},{"date":"2022-02-25","current":-9.269769,"twenty":-21.838448,"median":-10.661098,"eighty":-8.157856,"marketCap":912961010},{"date":"2022-03-04","current":-8.781382,"twenty":-21.800821,"median":-10.627712,"eighty":-8.159932,"marketCap":864860792},{"date":"2022-03-11","current":-9.24104,"twenty":-21.625625,"median":-10.599438,"eighty":-8.16125,"marketCap":910131586},{"date":"2022-03-18","current":-9.499598,"twenty":-21.49924,"median":-10.563952,"eighty":-8.174173,"marketCap":935596407},{"date":"2022-03-25","current":-9.078245,"twenty":-21.464221,"median":-10.552734,"eighty":-8.181555,"marketCap":894098179},{"date":"2022-04-01","current":-10.467769,"twenty":-21.240284,"median":-10.492287,"eighty":-8.191551,"marketCap":1126761127},{"date":"2022-04-08","current":-10.228049,"twenty":-21.149642,"median":-10.492287,"eighty":-8.193787,"marketCap":1100957437},{"date":"2022-04-14","current":-12.900888,"twenty":-21.039451,"median":-10.492287,"eighty":-8.198276,"marketCap":1388664524},{"date":"2022-04-22","current":-10.429872,"twenty":-20.971914,"median":-10.499338,"eighty":-8.207466,"marketCap":1122681857},{"date":"2022-04-29","current":-10.095773,"twenty":-20.908472,"median":-10.492287,"eighty":-8.211681,"marketCap":1086719127},{"date":"2022-05-06","current":-8.958011,"twenty":-20.861455,"median":-10.471142,"eighty":-8.221088,"marketCap":964249304},{"date":"2022-05-13","current":-8.404617,"twenty":-20.844139,"median":-10.448821,"eighty":-8.211681,"marketCap":1003233918},{"date":"2022-05-20","current":-9.198013,"twenty":-20.834693,"median":-10.421349,"eighty":-8.221088,"marketCap":1097939200},{"date":"2022-05-27","current":-7.526054,"twenty":-20.831716,"median":-10.403533,"eighty":-8.207466,"marketCap":898362533},{"date":"2022-06-03","current":-8.243248,"twenty":-20.809677,"median":-10.389178,"eighty":-8.193787,"marketCap":983971827},{"date":"2022-06-10","current":-8.332898,"twenty":-20.773299,"median":-10.384759,"eighty":-8.193787,"marketCap":994672989},{"date":"2022-06-17","current":-8.198424,"twenty":-20.744964,"median":-10.354491,"eighty":-8.179448,"marketCap":978621246},{"date":"2022-06-24","current":-8.790109,"twenty":-20.711905,"median":-10.335026,"eighty":-8.184663,"marketCap":1049248914},{"date":"2022-07-01","current":-8.449442,"twenty":-20.691921,"median":-10.323152,"eighty":-8.178395,"marketCap":1008584499},{"date":"2022-07-08","current":-9.466961,"twenty":-20.687549,"median":-10.318167,"eighty":-8.182609,"marketCap":1130042686},{"date":"2022-07-15","current":-9.28318,"twenty":-20.685143,"median":-10.298821,"eighty":-8.192879,"marketCap":1108105304},{"date":"2022-07-22","current":-8.740802,"twenty":-20.685143,"median":-10.266577,"eighty":-8.193787,"marketCap":1043363275},{"date":"2022-07-29","current":-8.61081,"twenty":-20.677272,"median":-10.257738,"eighty":-8.193787,"marketCap":1027846590},{"date":"2022-08-05","current":-9.951067,"twenty":-20.634231,"median":-10.228049,"eighty":-8.193787,"marketCap":1187828959},{"date":"2022-08-12","current":-8.14334,"twenty":-20.634231,"median":-10.193824,"eighty":-8.193787,"marketCap":1104619587},{"date":"2022-08-19","current":-8.456393,"twenty":-20.616458,"median":-10.133986,"eighty":-8.198424,"marketCap":1147084282},{"date":"2022-08-26","current":-7.735182,"twenty":-20.614304,"median":-10.125951,"eighty":-8.198424,"marketCap":1049254226},{"date":"2022-09-02","current":-8.012571,"twenty":-20.509821,"median":-10.090805,"eighty":-8.182609,"marketCap":1086881171},{"date":"2022-09-09","current":-8.333549,"twenty":-20.424511,"median":-10.060994,"eighty":-8.181555,"marketCap":1130420921},{"date":"2022-09-16","current":-8.15919,"twenty":-20.381857,"median":-10.025216,"eighty":-8.181555,"marketCap":1106769699},{"date":"2022-09-23","current":-7.196255,"twenty":-20.365249,"median":-9.993514,"eighty":-8.159083,"marketCap":976150448},{"date":"2022-09-30","current":-7.782734,"twenty":-20.324649,"median":-9.960349,"eighty":-8.146026,"marketCap":1055704559},{"date":"2022-10-07","current":-6.89509,"twenty":-20.250514,"median":-9.951067,"eighty":-8.135062,"marketCap":935298337},{"date":"2022-10-14","current":-6.998121,"twenty":-20.227233,"median":-9.937561,"eighty":-8.077801,"marketCap":949274059},{"date":"2022-10-21","current":-6.871314,"twenty":-20.161474,"median":-9.901345,"eighty":-8.056567,"marketCap":932073170},{"date":"2022-10-28","current":-7.430054,"twenty":-20.136431,"median":-9.880744,"eighty":-8.033672,"marketCap":1007864587},{"date":"2022-11-04","current":-7.0853,"twenty":-20.093453,"median":-9.868469,"eighty":-8.024905,"marketCap":961099670},{"date":"2022-11-11","current":-7.287397,"twenty":-20.00435,"median":-9.846345,"eighty":-8.006574,"marketCap":988513587},{"date":"2022-11-18","current":-6.408191,"twenty":-19.956905,"median":-9.828054,"eighty":-7.995885,"marketCap":959440787},{"date":"2022-11-25","current":-6.501636,"twenty":-19.890477,"median":-9.800131,"eighty":-7.968451,"marketCap":973431510},{"date":"2022-12-02","current":-6.62024,"twenty":-19.846329,"median":-9.76245,"eighty":-7.948042,"marketCap":991188967},{"date":"2022-12-09","current":-5.843925,"twenty":-19.776983,"median":-9.757117,"eighty":-7.918241,"marketCap":874958339},{"date":"2022-12-16","current":-6.055974,"twenty":-19.704409,"median":-9.745879,"eighty":-7.88923,"marketCap":906706520},{"date":"2022-12-23","current":-6.002063,"twenty":-19.680796,"median":-9.737368,"eighty":-7.885151,"marketCap":898634949},{"date":"2022-12-30","current":-6.577111,"twenty":-19.669279,"median":-9.699077,"eighty":-7.866381,"marketCap":984731710},{"date":"2023-01-06","current":-6.365063,"twenty":-19.649891,"median":-9.692629,"eighty":-7.843862,"marketCap":952983529},{"date":"2023-01-13","current":-6.483666,"twenty":-19.609956,"median":-9.650259,"eighty":-7.822756,"marketCap":970740987},{"date":"2023-01-20","current":-7.116219,"twenty":-19.559582,"median":-9.629971,"eighty":-7.807377,"marketCap":1065447424},{"date":"2023-01-27","current":-7.331862,"twenty":-19.535969,"median":-9.615242,"eighty":-7.782734,"marketCap":1097733710},{"date":"2023-02-03","current":-7.159348,"twenty":-19.461225,"median":-9.584859,"eighty":-7.754995,"marketCap":1071904681},{"date":"2023-02-10","current":-7.044338,"twenty":-19.457258,"median":-9.535198,"eighty":-7.732248,"marketCap":1054685329},{"date":"2023-02-17","current":-7.461248,"twenty":-19.457258,"median":-9.520574,"eighty":-7.709298,"marketCap":1117105481},{"date":"2023-02-24","current":-7.03715,"twenty":-19.444664,"median":-9.509544,"eighty":-7.687992,"marketCap":1053609120},{"date":"2023-03-03","current":-6.301284,"twenty":-19.422626,"median":-9.493855,"eighty":-7.646654,"marketCap":1032893853},{"date":"2023-03-10","current":-5.682995,"twenty":-19.399013,"median":-9.477341,"eighty":-7.616055,"marketCap":931545187},{"date":"2023-03-17","current":-5.673129,"twenty":-19.387993,"median":-9.468128,"eighty":-7.587875,"marketCap":929927921},{"date":"2023-03-24","current":-5.094305,"twenty":-19.361231,"median":-9.461001,"eighty":-7.548088,"marketCap":835048318},{"date":"2023-03-31","current":-5.281765,"twenty":-19.178623,"median":-9.446929,"eighty":-7.525158,"marketCap":865776371},{"date":"2023-04-06","current":-5.245589,"twenty":-19.1251,"median":-9.437072,"eighty":-7.512026,"marketCap":859846396},{"date":"2023-04-14","current":-5.433049,"twenty":-19.11408,"median":-9.422988,"eighty":-7.490369,"marketCap":890574449},{"date":"2023-04-21","current":-5.663262,"twenty":-19.049538,"median":-9.407112,"eighty":-7.459101,"marketCap":928310655},{"date":"2023-04-28","current":-6.15649,"twenty":-18.975549,"median":-9.36892,"eighty":-7.442722,"marketCap":1009159597},{"date":"2023-05-05","current":-7.039283,"twenty":-18.915729,"median":-9.363864,"eighty":-7.418061,"marketCap":1153865200},{"date":"2023-05-12","current":-6.810723,"twenty":-18.777198,"median":-9.349113,"eighty":-7.362868,"marketCap":1193824364},{"date":"2023-05-19","current":-6.753032,"twenty":-18.692191,"median":-9.337584,"eighty":-7.342882,"marketCap":1183711916},{"date":"2023-05-26","current":-6.771525,"twenty":-18.671726,"median":-9.323372,"eighty":-7.315764,"marketCap":1186953482},{"date":"2023-06-02","current":-6.734539,"twenty":-18.577274,"median":-9.300892,"eighty":-7.298852,"marketCap":1180470350},{"date":"2023-06-09","current":-6.768443,"twenty":-18.389943,"median":-9.284557,"eighty":-7.290458,"marketCap":1186413221},{"date":"2023-06-16","current":-6.401664,"twenty":-18.297064,"median":-9.264981,"eighty":-7.249516,"marketCap":1122122159},{"date":"2023-06-23","current":-5.729752,"twenty":-18.28447,"median":-9.24418,"eighty":-7.231948,"marketCap":1004345254},{"date":"2023-06-30","current":-5.489343,"twenty":-18.252986,"median":-9.233595,"eighty":-7.214095,"marketCap":962204894},{"date":"2023-07-07","current":-5.665026,"twenty":-18.202612,"median":-9.223038,"eighty":-7.194926,"marketCap":992999773},{"date":"2023-07-14","current":-6.312282,"twenty":-17.975925,"median":-9.21146,"eighty":-7.179788,"marketCap":1106454589},{"date":"2023-07-21","current":-6.164337,"twenty":-17.484771,"median":-9.151748,"eighty":-7.171037,"marketCap":1080522060},{"date":"2023-07-28","current":-5.689683,"twenty":-16.271054,"median":-9.132775,"eighty":-7.152878,"marketCap":997321861},{"date":"2023-08-04","current":-5.917764,"twenty":-14.799165,"median":-9.112846,"eighty":-7.130765,"marketCap":1037301177},{"date":"2023-08-11","current":-4.993133,"twenty":-14.41271,"median":-9.10082,"eighty":-7.101953,"marketCap":918187174},{"date":"2023-08-18","current":-4.820648,"twenty":-13.960254,"median":-9.085951,"eighty":-7.076801,"marketCap":886468975},{"date":"2023-08-25","current":-5.112088,"twenty":-13.776575,"median":-9.068669,"eighty":-7.045057,"marketCap":940061794},{"date":"2023-09-01","current":-5.150748,"twenty":-13.602279,"median":-9.044728,"eighty":-7.007837,"marketCap":947171046},{"date":"2023-09-08","current":-4.805779,"twenty":-13.455529,"median":-8.972798,"eighty":-6.979072,"marketCap":883734648},{"date":"2023-09-15","current":-10.528639,"twenty":-13.21365,"median":-8.968118,"eighty":-6.969506,"marketCap":1936111510},{"date":"2023-09-22","current":-10.489747,"twenty":-13.151006,"median":-8.968118,"eighty":-6.969506,"marketCap":1928959535},{"date":"2023-09-29","current":-10.55088,"twenty":-13.088761,"median":-8.968118,"eighty":-6.969506,"marketCap":1940201329},{"date":"2023-10-06","current":-9.637477,"twenty":-13.001031,"median":-8.968118,"eighty":-6.969506,"marketCap":1772235706},{"date":"2023-10-13","current":-9.515211,"twenty":-12.940021,"median":-8.968118,"eighty":-6.969506,"marketCap":1749752119},{"date":"2023-10-20","current":-10.015065,"twenty":-12.865635,"median":-8.968118,"eighty":-6.969506,"marketCap":1841670314},{"date":"2023-10-27","current":-10.507727,"twenty":-12.672735,"median":-8.958583,"eighty":-6.965401,"marketCap":1932265945},{"date":"2023-11-03","current":-10.500535,"twenty":-12.520569,"median":-8.958583,"eighty":-6.965401,"marketCap":1930943381},{"date":"2023-11-10","current":-8.940153,"twenty":-12.431833,"median":-8.949082,"eighty":-6.965401,"marketCap":1782872169},{"date":"2023-11-17","current":-9.492842,"twenty":-12.384119,"median":-8.949082,"eighty":-6.965401,"marketCap":1893090943},{"date":"2023-11-24","current":-10.715455,"twenty":-12.334984,"median":-8.949082,"eighty":-6.965401,"marketCap":2136908231},{"date":"2023-12-01","current":-10.648463,"twenty":-12.252824,"median":-8.949082,"eighty":-6.965401,"marketCap":2123548380},{"date":"2023-12-08","current":-11.21455,"twenty":-12.225037,"median":-8.958011,"eighty":-6.966388,"marketCap":2236439124},{"date":"2023-12-15","current":-11.686847,"twenty":-12.152639,"median":-8.958011,"eighty":-6.966388,"marketCap":2330626076},{"date":"2023-12-22","current":-11.639952,"twenty":-12.10182,"median":-8.958011,"eighty":-6.966388,"marketCap":2321274180},{"date":"2023-12-29","current":-11.974915,"twenty":-12.077207,"median":-8.949082,"eighty":-6.965401,"marketCap":2388073437},{"date":"2024-01-05","current":-11.646651,"twenty":-12.037531,"median":-8.940153,"eighty":-6.964415,"marketCap":2322610165},{"date":"2024-01-12","current":-12.484058,"twenty":-12.02672,"median":-8.940153,"eighty":-6.964415,"marketCap":2489608308},{"date":"2024-01-19","current":-12.125648,"twenty":-12.016913,"median":-8.938652,"eighty":-6.963428,"marketCap":2418133103},{"date":"2024-01-26","current":-12.477359,"twenty":-12.00979,"median":-8.940153,"eighty":-6.964415,"marketCap":2488272323},{"date":"2024-02-02","current":-12.46396,"twenty":-12.00979,"median":-8.940153,"eighty":-6.964415,"marketCap":2485600352},{"date":"2024-02-09","current":-12.880989,"twenty":-12.00979,"median":-8.940153,"eighty":-6.964415,"marketCap":2568765427},{"date":"2024-02-16","current":-12.366821,"twenty":-12.00979,"median":-8.940153,"eighty":-6.964415,"marketCap":2466228568},{"date":"2024-02-23","current":-12.299829,"twenty":-12.00979,"median":-8.940153,"eighty":-6.964415,"marketCap":2452868717},{"date":"2024-03-01","current":-12.747748,"twenty":-12.025825,"median":-8.949082,"eighty":-6.965401,"marketCap":2734761581},{"date":"2024-03-08","current":-15.438497,"twenty":-12.025825,"median":-8.949082,"eighty":-6.965401,"marketCap":3312005280},{"date":"2024-03-15","current":-13.880117,"twenty":-12.025825,"median":-8.949082,"eighty":-6.965401,"marketCap":2977687570},{"date":"2024-03-22","current":-16.335746,"twenty":-12.025825,"median":-8.949082,"eighty":-6.965401,"marketCap":3504491233},{"date":"2024-03-28","current":-16.139586,"twenty":-12.025825,"median":-8.949082,"eighty":-6.965401,"marketCap":3462409284},{"date":"2024-04-05","current":-16.946021,"twenty":-12.00979,"median":-8.940153,"eighty":-6.964415,"marketCap":3635412854},{"date":"2024-04-12","current":-17.447318,"twenty":-12.00979,"median":-8.940153,"eighty":-6.964415,"marketCap":3742955614},{"date":"2024-04-19","current":-15.623759,"twenty":-12.00979,"median":-8.940153,"eighty":-6.964415,"marketCap":3351749343},{"date":"2024-04-26","current":-15.522839,"twenty":-12.025825,"median":-8.949082,"eighty":-6.965401,"marketCap":3330099153},{"date":"2024-05-03","current":-17.170925,"twenty":-12.025825,"median":-8.949082,"eighty":-6.965401,"marketCap":3683661347},{"date":"2024-05-10","current":-18.139955,"twenty":-12.025825,"median":-8.949082,"eighty":-6.965401,"marketCap":3891546468},{"date":"2024-05-17","current":-17.385236,"twenty":-12.025825,"median":-8.949082,"eighty":-6.965401,"marketCap":4093597164},{"date":"2024-05-24","current":-16.286727,"twenty":-12.025825,"median":-8.949082,"eighty":-6.965401,"marketCap":3834937971},{"date":"2024-05-31","current":-14.873402,"twenty":-12.025825,"median":-8.949082,"eighty":-6.965401,"marketCap":3502150839},{"date":"2024-06-07","current":-14.973876,"twenty":-12.025825,"median":-8.949082,"eighty":-6.965401,"marketCap":3525808692},{"date":"2024-06-14","current":-15.181521,"twenty":-12.025825,"median":-8.949082,"eighty":-6.965401,"marketCap":3574701588},{"date":"2024-06-21","current":-15.265248,"twenty":-12.00979,"median":-8.940153,"eighty":-6.964415,"marketCap":3594416465},{"date":"2024-06-28","current":-15.000669,"twenty":-12.00979,"median":-8.940153,"eighty":-6.964415,"marketCap":3532117452},{"date":"2024-07-05","current":-14.679154,"twenty":-12.00979,"median":-8.940153,"eighty":-6.964415,"marketCap":3456412323},{"date":"2024-07-12","current":-17.974679,"twenty":-12.00979,"median":-8.940153,"eighty":-6.964415,"marketCap":4232389901},{"date":"2024-07-19","current":-17.636419,"twenty":-12.00979,"median":-8.940153,"eighty":-6.964415,"marketCap":4152741796},{"date":"2024-07-26","current":-18.205768,"twenty":-12.00979,"median":-8.940153,"eighty":-6.964415,"marketCap":4286802963},{"date":"2024-08-02","current":-16.675224,"twenty":-12.00979,"median":-8.940153,"eighty":-6.964415,"marketCap":3926415002},{"date":"2024-08-09","current":-14.747801,"twenty":-12.00979,"median":-8.940153,"eighty":-6.964415,"marketCap":3812896460},{"date":"2024-08-16","current":-15.97988,"twenty":-12.036548,"median":-8.940153,"eighty":-6.964415,"marketCap":4131438188},{"date":"2024-08-23","current":-16.453518,"twenty":-12.048412,"median":-8.940153,"eighty":-6.964415,"marketCap":4253892671},{"date":"2024-08-30","current":-16.425657,"twenty":-12.092151,"median":-8.940153,"eighty":-6.964415,"marketCap":4246689466},{"date":"2024-09-06","current":-15.599112,"twenty":-12.125526,"median":-8.940153,"eighty":-6.964415,"marketCap":4032994387},{"date":"2024-09-13","current":-16.654737,"twenty":-12.17296,"median":-8.940153,"eighty":-6.964415,"marketCap":4305915818},{"date":"2024-09-20","current":-16.453518,"twenty":-12.227054,"median":-8.940153,"eighty":-6.964415,"marketCap":4253892671},{"date":"2024-09-27","current":-15.710556,"twenty":-12.272743,"median":-8.940153,"eighty":-6.964415,"marketCap":4061807207},{"date":"2024-10-04","current":-16.450423,"twenty":-12.32899,"median":-8.940153,"eighty":-6.964415,"marketCap":4253092315},{"date":"2024-10-11","current":-18.505811,"twenty":-12.35557,"median":-8.940153,"eighty":-6.964415,"marketCap":4784492315},{"date":"2024-10-18","current":-20.577877,"twenty":-12.404669,"median":-8.940153,"eighty":-6.964415,"marketCap":5320204194},{"date":"2024-10-25","current":-20.184358,"twenty":-12.429918,"median":-8.940153,"eighty":-6.964415,"marketCap":5218463955},{"date":"2024-11-01","current":-19.742085,"twenty":-12.458746,"median":-8.940153,"eighty":-6.964415,"marketCap":5104118730},{"date":"2024-11-08","current":-21.135071,"twenty":-12.490087,"median":-8.940153,"eighty":-6.964415,"marketCap":5464261170},{"date":"2024-11-15","current":-18.259879,"twenty":-12.591928,"median":-8.940153,"eighty":-6.964415,"marketCap":5074602949},{"date":"2024-11-22","current":-18.707032,"twenty":-12.64417,"median":-8.940153,"eighty":-6.964415,"marketCap":5198871369},{"date":"2024-11-29","current":-19.087447,"twenty":-12.683273,"median":-8.940153,"eighty":-6.964415,"marketCap":5304592264},{"date":"2024-12-06","current":-19.64472,"twenty":-12.8235,"median":-8.940153,"eighty":-6.964415,"marketCap":5459464101},{"date":"2024-12-13","current":-17.90616,"twenty":-12.91421,"median":-8.940153,"eighty":-6.964415,"marketCap":4976301064},{"date":"2024-12-20","current":-17.886139,"twenty":-12.966659,"median":-8.940153,"eighty":-6.964415,"marketCap":4970736807},{"date":"2024-12-27","current":-17.30217,"twenty":-12.997756,"median":-8.940153,"eighty":-6.964415,"marketCap":4808445959},{"date":"2025-01-03","current":-17.735975,"twenty":-13.015908,"median":-8.940153,"eighty":-6.964415,"marketCap":4929004875},{"date":"2025-01-10","current":-13.544746,"twenty":-13.001031,"median":-8.938652,"eighty":-6.963428,"marketCap":3764220279},{"date":"2025-01-17","current":-12.463569,"twenty":-12.951811,"median":-8.938652,"eighty":-6.963428,"marketCap":3463750368},{"date":"2025-01-24","current":-12.944092,"twenty":-12.946445,"median":-8.938652,"eighty":-6.963428,"marketCap":3597292551},{"date":"2025-01-31","current":-13.447974,"twenty":-12.982147,"median":-8.938652,"eighty":-6.963428,"marketCap":3737326368},{"date":"2025-02-07","current":-12.340101,"twenty":-13.020412,"median":-8.938652,"eighty":-6.963428,"marketCap":3429437446},{"date":"2025-02-14","current":-11.749458,"twenty":-13.020412,"median":-8.938652,"eighty":-6.963428,"marketCap":3265291846},{"date":"2025-02-21","current":-12.500275,"twenty":-13.002744,"median":-8.938652,"eighty":-6.963428,"marketCap":3473951507},{"date":"2025-02-28","current":-11.156794,"twenty":-13.002744,"median":-8.938652,"eighty":-6.963428,"marketCap":3329276689},{"date":"2025-03-07","current":-10.377253,"twenty":-13.007494,"median":-8.937152,"eighty":-6.962441,"marketCap":3096655344},{"date":"2025-03-14","current":-10.748315,"twenty":-13.007494,"median":-8.968118,"eighty":-6.97803,"marketCap":3207383104},{"date":"2025-03-21","current":-10.732724,"twenty":-13.007494,"median":-9.020788,"eighty":-7.011785,"marketCap":3202730677},{"date":"2025-03-28","current":-10.829387,"twenty":-13.007494,"median":-9.054304,"eighty":-7.03715,"marketCap":3231575724},{"date":"2025-04-04","current":-8.384746,"twenty":-13.007494,"median":-9.072285,"eighty":-7.047932,"marketCap":2502075186},{"date":"2025-04-11","current":-9.076978,"twenty":-13.002744,"median":-9.074632,"eighty":-7.076801,"marketCap":2708642941},{"date":"2025-04-17","current":-9.485458,"twenty":-13.002744,"median":-9.080639,"eighty":-7.080396,"marketCap":2830536525},{"date":"2025-04-25","current":-10.162754,"twenty":-13.007494,"median":-9.078245,"eighty":-7.080278,"marketCap":3032647132},{"date":"2025-05-02","current":-10.592608,"twenty":-13.007494,"median":-9.078245,"eighty":-7.080278,"marketCap":3160919023},{"date":"2025-05-09","current":-8.755792,"twenty":-13.007494,"median":-9.076978,"eighty":-7.080278,"marketCap":2874106388},{"date":"2025-05-16","current":-8.915611,"twenty":-13.007494,"median":-9.054304,"eighty":-7.080278,"marketCap":2926567261},{"date":"2025-05-23","current":-8.59312,"twenty":-13.007494,"median":-9.020788,"eighty":-7.080278,"marketCap":2820708714},{"date":"2025-05-30","current":-8.71013,"twenty":-13.007494,"median":-8.972798,"eighty":-7.080278,"marketCap":2859117567},{"date":"2025-06-06","current":-9.223834,"twenty":-13.007494,"median":-9.020788,"eighty":-7.080278,"marketCap":3027741801},{"date":"2025-06-13","current":-9.181025,"twenty":-13.007494,"median":-9.044799,"eighty":-7.080278,"marketCap":3013689782},{"date":"2025-06-20","current":-8.704422,"twenty":-13.010724,"median":-9.020666,"eighty":-7.079409,"marketCap":2857243965},{"date":"2025-06-27","current":-8.558873,"twenty":-13.010724,"median":-8.968555,"eighty":-7.079409,"marketCap":2809467098},{"date":"2025-07-03","current":-8.504648,"twenty":-13.010724,"median":-8.946433,"eighty":-7.079409,"marketCap":2791667874},{"date":"2025-07-11","current":-9.129655,"twenty":-13.010724,"median":-8.935157,"eighty":-7.079409,"marketCap":2996827358},{"date":"2025-07-18","current":-9.423607,"twenty":-13.010724,"median":-8.968555,"eighty":-7.079409,"marketCap":3093317892},{"date":"2025-07-25","current":-8.678737,"twenty":-13.010724,"median":-8.968555,"eighty":-7.079409,"marketCap":2848812753},{"date":"2025-08-01","current":-8.159326,"twenty":-13.010724,"median":-8.968555,"eighty":-7.079409,"marketCap":2678314916},{"date":"2025-08-08","current":-7.956698,"twenty":-13.010724,"median":-8.968555,"eighty":-7.079409,"marketCap":2611802024},{"date":"2025-08-15","current":-7.560379,"twenty":-13.010724,"median":-8.968555,"eighty":-7.068699,"marketCap":2796085261},{"date":"2025-08-22","current":-7.486532,"twenty":-13.010724,"median":-8.968555,"eighty":-7.068699,"marketCap":2768774223},{"date":"2025-08-29","current":-7.804837,"twenty":-13.010724,"median":-8.968555,"eighty":-7.068699,"marketCap":2886494216},{"date":"2025-09-05","current":-8.721556,"twenty":-13.013953,"median":-8.968992,"eighty":-7.063986,"marketCap":3225527794},{"date":"2025-09-12","current":-8.589141,"twenty":-13.010724,"median":-8.987106,"eighty":-7.068699,"marketCap":3176556277},{"date":"2025-09-19","current":-9.034768,"twenty":-13.010724,"median":-9.001778,"eighty":-7.068699,"marketCap":3341364267},{"date":"2025-09-26","current":-9.139172,"twenty":-13.010724,"median":-9.020666,"eighty":-7.068699,"marketCap":3379976424},{"date":"2025-10-03","current":-10.570271,"twenty":-13.010724,"median":-9.046349,"eighty":-7.068699,"marketCap":3909245510},{"date":"2025-10-10","current":-11.652508,"twenty":-13.010724,"median":-9.06737,"eighty":-7.068699,"marketCap":4309493485},{"date":"2025-10-17","current":-10.773986,"twenty":-13.010724,"median":-9.080639,"eighty":-7.068699,"marketCap":3984586306},{"date":"2025-10-24","current":-10.20613,"twenty":-13.010724,"median":-9.093916,"eighty":-7.068699,"marketCap":3774573839},{"date":"2025-10-31","current":-11.020991,"twenty":-13.010724,"median":-9.102394,"eighty":-7.085701,"marketCap":4075937020},{"date":"2025-11-07","current":-9.680319,"twenty":-13.010724,"median":-9.112689,"eighty":-7.127412,"marketCap":4095713979},{"date":"2025-11-14","current":-9.291886,"twenty":-13.010724,"median":-9.121574,"eighty":-7.158629,"marketCap":3931368931},{"date":"2025-11-21","current":-9.412996,"twenty":-13.010724,"median":-9.137437,"eighty":-7.177318,"marketCap":3982610524},{"date":"2025-11-28","current":-10.218159,"twenty":-13.010724,"median":-9.168122,"eighty":-7.187378,"marketCap":4323272230},{"date":"2025-12-05","current":-10.635318,"twenty":-13.010724,"median":-9.212779,"eighty":-7.213697,"marketCap":4499771052},{"date":"2025-12-12","current":-11.059205,"twenty":-13.010724,"median":-9.224371,"eighty":-7.239267,"marketCap":4679116630},{"date":"2025-12-17","current":-10.90221,"twenty":-13.010724,"median":-9.228039,"eighty":-7.268484,"marketCap":4612692342}],"updateTime":1766065283153},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CRNX\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2592468639","title":"Crinetics Pharmaceuticals Grants $577,000 Severance and Bonus Eligibility to Departing Chief Medical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2592468639","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592468639?lang=en_us&edition=fundamental","pubTime":"2025-12-18 06:00","pubTimestamp":1766008846,"startTime":"0","endTime":"0","summary":"Crinetics Pharmaceuticals Inc. has announced new compensation terms for Dana Pizzuti, M.D., as she steps down from her role as Chief Medical and Development Officer effective December 31, 2025. Under a Transition Agreement, Dr. Pizzuti will receive $577,000 in cash severance, equivalent to twelve months of her current base salary. She will also be eligible for an annual cash bonus for 2025, a prorated bonus for 2026, reimbursement of up to $15,000 for legal fees related to the agreement, COBRA premium reimbursements for up to twelve months, and payment of up to $6,500 for a Board of Directors development training course. Dr. Pizzuti will continue with the company as a Strategic Regulatory and Development Advisor starting January 1, 2026.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nNDL1Cxtvd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","CRNX"],"gpt_icon":0},{"id":"2590491485","title":"Crinetics Pharmaceuticals Doses First Patient in Phase 3 Atumelnant Trial for Congenital Adrenal Hyperplasia","url":"https://stock-news.laohu8.com/highlight/detail?id=2590491485","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590491485?lang=en_us&edition=fundamental","pubTime":"2025-12-12 05:05","pubTimestamp":1765487120,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Crinetics Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire  on December 11, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nNDL4tPgSM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","SG9999014039.USD","SG9999014013.SGD","BK4588","LU2095319765.USD","LU0314104364.USD","BK4139","SG9999014021.USD","LU2210149790.SGD","CRNX","IE00BGHQF748.EUR","NDAQ","IE00B3QW5Z07.USD","IE00BKPKM429.USD","IE00B64PRP62.GBP","BK4007","BK4585","LU2210150020.SGD","SG9999014005.SGD"],"gpt_icon":0},{"id":"2590199549","title":"Crinetics Announces First Patient Dosed in Pivotal Adult Trial of Atumelnant in Congenital Adrenal Hyperplasia (Cah)","url":"https://stock-news.laohu8.com/highlight/detail?id=2590199549","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590199549?lang=en_us&edition=fundamental","pubTime":"2025-12-12 05:05","pubTimestamp":1765487100,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nTUA4XQG3R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CRNX","BK4139","BK4007"],"gpt_icon":0},{"id":"2590553924","title":"Crinetics Pharmaceuticals Grants Stock Options and RSUs to New Employees Under 2021 Inducement Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2590553924","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590553924?lang=en_us&edition=fundamental","pubTime":"2025-12-11 05:34","pubTimestamp":1765402496,"startTime":"0","endTime":"0","summary":"Crinetics Pharmaceuticals Inc. has granted non-qualified stock options to purchase a total of 39,575 shares and 26,525 restricted stock units  to nine new non-executive employees under its 2021 Employment Inducement Incentive Award Plan. The stock options have an exercise price of $48.06 per share, matching the company's closing share price on the grant date. Stock options will vest over four years, with 25% vesting after one year and the remainder vesting in equal monthly installments over the following three years. RSUs will vest in equal annual installments over four years, starting on the one-year anniversary of the grant date. Both stock option and RSU awards are subject to continued employment and the terms of the 2021 Inducement Plan.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be i","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nNDL6kr8WB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4585","LU2210149790.SGD","BK4139","BK4112","LU2210150020.SGD","IE00BGHQF748.EUR","LU2095319765.USD","BK4588","SG9999014021.USD","SG9999014039.USD","LU0314104364.USD","NDAQ","IE00B3QW5Z07.USD","SG9999014005.SGD","CRNX","IE00BKPKM429.USD","IE00B64PRP62.GBP","SG9999014013.SGD"],"gpt_icon":0},{"id":"2590553944","title":"Crinetics Pharmaceuticals Announces December 2025 Inducement Grants Under  Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2590553944","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590553944?lang=en_us&edition=fundamental","pubTime":"2025-12-11 05:34","pubTimestamp":1765402486,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nTUABCVCG8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","CRNX","BK4139"],"gpt_icon":0},{"id":"2589858805","title":"Did First-in-Human BRAVESST2 Trial of CRN09682 Just Shift Crinetics Pharmaceuticals' (CRNX) Investment Narrative?","url":"https://stock-news.laohu8.com/highlight/detail?id=2589858805","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589858805?lang=en_us&edition=fundamental","pubTime":"2025-12-08 02:11","pubTimestamp":1765131099,"startTime":"0","endTime":"0","summary":"Crinetics Pharmaceuticals recently dosed the first patient in its Phase 1/2 BRAVESST2 trial of CRN09682 for metastatic or locally advanced somatostatin receptor type 2 (SST2)-positive neuroendocrine and other SST2-expressing solid tumors.\nThe trial marks the first clinical test of Crinetics’ nonpeptide drug conjugate platform, which aims to deliver potent cytotoxic therapy selectively to SST2-expressing tumor cells using small-molecule manufacturing rather than antibody or...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crnx/crinetics-pharmaceuticals/news/did-first-in-human-bravesst2-trial-of-crn09682-just-shift-cr","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crnx/crinetics-pharmaceuticals/news/did-first-in-human-bravesst2-trial-of-crn09682-just-shift-cr","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","CRNX","BK4007"],"gpt_icon":0},{"id":"2588024954","title":"Crinetics Pharmaceuticals Chief Medical and Development Officer Dana Pizzuti Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2588024954","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588024954?lang=en_us&edition=fundamental","pubTime":"2025-12-04 05:29","pubTimestamp":1764797343,"startTime":"0","endTime":"0","summary":"Dana Pizzuti, Chief Medical and Development Officer of Crinetics Pharmaceuticals Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Crinetics Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 03, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nNDL7R65rP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Crinetics Pharmaceuticals Chief Medical and Development Officer Dana Pizzuti Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRNX","BK4007","BK4139"],"gpt_icon":0},{"id":"2588356049","title":"BRIEF-Crinetics Announces First Patient Dosed In Phase 1/2 Trial Evaluating Crn09682","url":"https://stock-news.laohu8.com/highlight/detail?id=2588356049","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588356049?lang=en_us&edition=fundamental","pubTime":"2025-12-03 21:07","pubTimestamp":1764767268,"startTime":"0","endTime":"0","summary":"BRIEF-Crinetics Announces First Patient Dosed In Phase 1/2 Trial Evaluating Crn09682 Dec 3 (Reuters) - Crinetics Pharmaceuticals Inc CRNX.O:CRINETICS ANNOUNCES FIRST PATIENT DOSED IN PHASE 1/2 TRIAL E","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nFWN3X8186:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRNX","BK4139","BK4007"],"gpt_icon":0},{"id":"2588879049","title":"Crinetics Announces First Patient Dosed in Phase 1/2 Trial Evaluating Crn09682 for the Treatment of Neuroendocrine Tumors and Other Somatostatin Receptor 2-Expressing Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2588879049","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588879049?lang=en_us&edition=fundamental","pubTime":"2025-12-03 21:05","pubTimestamp":1764767132,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nFWN3X8186:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CRNX","BK4007","BK4139"],"gpt_icon":0},{"id":"2588046287","title":"Crinetics Pharmaceuticals Doses First Patient in Phase 1/2 Trial of CRN09682 for Neuroendocrine Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2588046287","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588046287?lang=en_us&edition=fundamental","pubTime":"2025-12-03 21:00","pubTimestamp":1764766848,"startTime":"0","endTime":"0","summary":"Crinetics Pharmaceuticals Inc. has announced the dosing of the first patient in its Phase 1/2 clinical trial evaluating CRN09682 for the treatment of metastatic or locally advanced somatostatin receptor type 2 -positive neuroendocrine tumors and other SST2-expressing solid tumors. CRN09682 is the lead candidate from Crinetics' proprietary nonpeptide drug conjugate  platform, designed to target SST2-expressing tumor cells and deliver a cytotoxic payload directly within the tumor. The BRAVESST2 trial is a first-in-human, open-label, dose-escalation study with a planned dose expansion phase to assess the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of CRN09682. Up to 150 participants are expected to be enrolled. The results of the study have not yet been presented.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nNDL5CF2HD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","IE00B3QW5Z07.USD","NDAQ","LU2095319765.USD","BK4139","LU0314104364.USD","IE00B64PRP62.GBP","BK4112","IE00BGHQF748.EUR","LU2210149790.SGD","LU2210150020.SGD","IE00BKPKM429.USD","BK4585","BK4588","CRNX"],"gpt_icon":0},{"id":"2587809762","title":"Why Crinetics Pharmaceuticals (CRNX) Is Up 6.3% After Pivotal Phase 3 Paltusotine Trial Launch","url":"https://stock-news.laohu8.com/highlight/detail?id=2587809762","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2587809762?lang=en_us&edition=fundamental","pubTime":"2025-11-30 03:14","pubTimestamp":1764443651,"startTime":"0","endTime":"0","summary":"Crinetics Pharmaceuticals recently announced that the first patient has been randomized in the pivotal Phase 3 CAREFNDR trial, evaluating once-daily, oral paltusotine in adults with carcinoid syndrome due to well-differentiated neuroendocrine tumors.\nThis milestone reflects the company's effort to expand the use of paltusotine, which is already FDA-approved for acromegaly, into an additional patient population with significant unmet medical needs.\nWe'll explore what the advancement of...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crnx/crinetics-pharmaceuticals/news/why-crinetics-pharmaceuticals-crnx-is-up-63-after-pivotal-ph","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crnx/crinetics-pharmaceuticals/news/why-crinetics-pharmaceuticals-crnx-is-up-63-after-pivotal-ph","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["CRNX","BK4007","BK4139"],"gpt_icon":0},{"id":"2585621150","title":"Crinetics randomizes first patient in CAREFNDR trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2585621150","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585621150?lang=en_us&edition=fundamental","pubTime":"2025-11-21 05:15","pubTimestamp":1763673359,"startTime":"0","endTime":"0","summary":"Crinetics (CRNX) announced the first patient has been randomized in the pivotal Phase 3 CAREFNDR trial, a multicenter, randomized, double-blind, pl...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/crinetics-randomizes-first-patient-in-carefndr-trial-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/crinetics-randomizes-first-patient-in-carefndr-trial-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CRNX","BK4139","BK4007"],"gpt_icon":0},{"id":"2585157274","title":"Crinetics Launches Phase 3 Trial of Paltusotine for Carcinoid Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2585157274","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585157274?lang=en_us&edition=fundamental","pubTime":"2025-11-21 05:05","pubTimestamp":1763672723,"startTime":"0","endTime":"0","summary":"Crinetics Pharmaceuticals Inc. has announced the initiation of the pivotal Phase 3 CAREFNDR trial, evaluating the efficacy and safety of once-daily, oral paltusotine in adults with carcinoid syndrome due to well-differentiated neuroendocrine tumors. This multicenter, randomized, double-blind, placebo-controlled study will enroll 141 adults, both treatment-nave and previously treated patients. Participants will be randomized in a 2:1 ratio to receive either paltusotine 80 mg or placebo. The primary endpoint is the change in flushing episodes per day from baseline to Week 12, with change in bowel movements per day as a key secondary endpoint. The trial also includes a 104-week open-label extension to assess long-term efficacy, safety, and tumor control. Results from this Phase 3 study have not yet been presented. Global enrollment is expected throughout 2025 and 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT striv","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251120:nNDL1FwSp8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","IE00B3QW5Z07.USD","BK4112","BK4585","LU0314104364.USD","LU2095319765.USD","BK4139","IE00B64PRP62.GBP","IE00BGHQF748.EUR","BK4588","CRNX","LU2210149790.SGD","LU2210150020.SGD","NDAQ","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2585157244","title":"Crinetics Announces First Patient Randomized in Pivotal Phase 3 Carefndr Trial Evaluating Paltusotine in Carcinoid Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2585157244","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585157244?lang=en_us&edition=fundamental","pubTime":"2025-11-21 05:05","pubTimestamp":1763672700,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251120:nTUA48Q7B1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CRNX","BK4007"],"gpt_icon":0},{"id":"2584219469","title":"Crinetics Pharmaceuticals Announces November 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2584219469","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584219469?lang=en_us&edition=fundamental","pubTime":"2025-11-20 01:15","pubTimestamp":1763572557,"startTime":"0","endTime":"0","summary":"Nov 11 (Reuters) - Crinetics Pharmaceuticals Inc ::*CRINETICS PHARMACEUTICALS ANNOUNCES NOVEMBER 2025 INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 10-NOV-202521:28:41.033 GMT","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nRSDtHkvr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","CRNX"],"gpt_icon":0},{"id":"2584929397","title":"Crinetics Pharmaceuticals Q3 Net Income USD -130.091 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2584929397","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584929397?lang=en_us&edition=fundamental","pubTime":"2025-11-20 00:58","pubTimestamp":1763571510,"startTime":"0","endTime":"0","summary":"Nov 06 (Reuters) - Crinetics Pharmaceuticals Q3 revenue USD 143 thousand vs. IBES estimate USD 637.2 thousand.:  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 06-NOV-202521:05:57.43 GMT","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nRSD98GNmS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRNX","BK4139","BK4007"],"gpt_icon":0},{"id":"2582386559","title":"BRIEF-Crinetics Pharmaceuticals Announces November 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2582386559","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582386559?lang=en_us&edition=fundamental","pubTime":"2025-11-11 06:33","pubTimestamp":1762813987,"startTime":"0","endTime":"0","summary":"BRIEF-Crinetics Pharmaceuticals Announces November 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Nov 11 (Reuters) - Crinetics Pharmaceuticals Inc CRNX.O:CRINETICS PHARMACEUTICALS ANNOUNCE","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nTUA21BXG3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","CRNX"],"gpt_icon":0},{"id":"2582460388","title":"Crinetics Pharmaceuticals Grants Stock Options and RSUs to New Employees Under 2021 Inducement Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2582460388","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582460388?lang=en_us&edition=fundamental","pubTime":"2025-11-11 05:28","pubTimestamp":1762810132,"startTime":"0","endTime":"0","summary":"Crinetics Pharmaceuticals Inc. has granted non-qualified stock options to purchase a total of 37,675 shares and 25,300 restricted stock units  to 11 new non-executive employees under its 2021 Employment Inducement Incentive Award Plan. The stock options carry an exercise price of $41.45 per share, equal to the company's closing stock price on November 10, 2025. The stock options will vest over four years, with 25% vesting after one year and the remainder vesting in equal monthly installments over the following three years. The RSUs will vest in equal annual installments over four years, beginning on the first anniversary of the grant date. Both awards are subject to the employees' continued employment with Crinetics.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nNDLbYX4Sc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRNX","BK4139","BK4007"],"gpt_icon":0},{"id":"2582805740","title":"Cantor Fitzgerald Sticks to Its Buy Rating for Crinetics Pharmaceuticals (CRNX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2582805740","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582805740?lang=en_us&edition=fundamental","pubTime":"2025-11-11 00:45","pubTimestamp":1762793132,"startTime":"0","endTime":"0","summary":"Cantor Fitzgerald analyst Joshua Schimmer maintained a Buy rating on Crinetics Pharmaceuticals on November 6 and set a price target of $90.00. Acco...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/cantor-fitzgerald-sticks-to-its-buy-rating-for-crinetics-pharmaceuticals-crnx-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/cantor-fitzgerald-sticks-to-its-buy-rating-for-crinetics-pharmaceuticals-crnx-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CRNX"],"gpt_icon":0},{"id":"2582761348","title":"Crinetics price target raised to $45 from $40 at Goldman Sachs","url":"https://stock-news.laohu8.com/highlight/detail?id=2582761348","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582761348?lang=en_us&edition=fundamental","pubTime":"2025-11-10 20:36","pubTimestamp":1762778193,"startTime":"0","endTime":"0","summary":"Goldman Sachs raised the firm’s price target on Crinetics (CRNX) to $45 from $40 and keeps a Neutral rating on the shares. Published first on TheFl...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/crinetics-price-target-raised-to-45-from-40-at-goldman-sachs-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/crinetics-price-target-raised-to-45-from-40-at-goldman-sachs-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1868837136.USD","IE00BSNM7G36.USD","LU0251142724.SGD","LU0251131958.USD","BK4533","LU2237443895.HKD","LU2237443549.SGD","LU0096364046.USD","LU0106831901.USD","LU1668664300.SGD","LU1804176565.USD","LU2265009873.SGD","LU2471134952.CNY","LU2237443465.HKD","BK4127","IE00BFXG1179.USD","LU2471134523.USD","BK4550","LU2471134879.HKD","LU2237443382.USD","IE0004091025.USD","BK4588","LU0742534661.SGD","IE00B19Z3B42.SGD","LU1791807156.HKD","BK4139","IE00B19Z3581.USD","BK4552","CRNX","LU1868837300.USD","BK4585","LU1868836914.USD","LU0048573561.USD","LU1894683264.USD","LU0345770993.USD","LU2237443622.USD","LU2237438978.USD","LU1868836591.USD","BK4007","IE0002270589.USD","LU2471134796.USD","LU2750360641.GBP","LU0345770308.USD","LU2237443978.SGD","LU1868836757.USD","IE0034235188.USD","IE0004086264.USD","LU1894683348.USD","BK4504","LU0061475181.USD"],"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":1,"totalSize":87,"code":"91000000","status":"200"}]}}